The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma by Uyl-de Groot, C.A. (Carin) et al.
Prognosis in Advanced Colorectal Cancer 457 
12. 
13. 
14. 
15. 
tal cancer patients with liver metastases. J Surg Oncol 1987, 34, 
81-86. 
Edler L, HeimME, Quintero C, Brummer T, Queisser W. Prognos- 
tic factors of advanced colorectal cancer patients. Eur3 Cancer Clin 
Oncoll986,22, 1231-1237. 
Steinberg J, Erlichman C, Gadalla T, Fine S, Wong T. Prognostic 
factors in patients with metastatic olorectal cancer receiving S- 
fluorouracil and folinic acid. Eur._7 Cancer 1992,28A, 1817-1820. 
Graf W, Glirnelius B, Palman L, Berstrom. Determinants of 
prognosis in advanced colorectal cancer. Eur 3 Cancer 1991, 27, 
1119-1123. 
Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Bio- 
chemical modulation of 5fluorouracil: a randomized comparison 
Pergamon 
16. 
17. 
18. 
of sequential methotrexate, 5-fluorouracil, and leucovorin versus 
sequential 5-fluorouracil and leucovorin in patients with advanced 
colorectal cancer. Ann Oncoll993,4,235-240. 
Cox DR. Regression models and life-tables. 3 R Stat Sue 1972,34, 
187-220. 
Fortner JG, Silva JS, Cox EB, Golbey RB, Gallowitz H, Maclean B. 
Multivariate analysis of a personal series of 247 patients with liver 
metastases from colorectal cancer. II Treatment by intrahepatic 
chemotherapy. AnnSurg 1984,199,317-324. 
Tartter PI. Pretreatment prognostic factors in colorectal cancer 
patients with synchronous liver metastases. Eurg Surg Oncol 1987, 
13,485491. 
European~oumalo/Cu2ncnVol. 30A, No. 4, pp. 457-459, 1994 
Copynght Q 1994 Elxvler Science Ltd 
Printed in Great Britain. All rights reserved 
0959-8049194 $7.00 to.00 
0959-8049(94)E0037-5 
The Costs of Peripheral Blood Progenitor Cell 
Reinfusion Mobilised by Granulocyte Colony- 
stimulating Factor Following High Dose 
Melphalan as Compared with Conventional 
Therapy in Multiple Myeloma 
C.A. Uyl-de Groot, G. J. Ossenkoppele, A.A.P.M. van Riet and F.F.H. Rutten 
In a retrospective study, we calculated the treatment costs of 26 patients, who received either high dose melphalan 
combined with granulocyte colony-stimulating factor (G-CSF; lilgrastim)(n=7) or without GCSF (n=ll) or 
alternatively, peripheral blood progenitor cell reinfusion (PBPC) mobilised by G-CSF following high dose 
melphalan. In comparison with the control group, a shortening of the pancytopenic period and platelet recovery 
was noticed in the PBPC group. This resulted in a reduction in hospital costs, diagnostics, laboratory services, 
total parenteral nutrition and transfusions. The average costs per treatment in the PBPC group amounted to about 
US.$l7 908 as compared to US$32 223 in the control group, implying a cost reduction of 44% when changing to 
PBPC reinfusion. 
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INTRODUCTION 
HIGH DOSE melphalan is associated with high response rates in 
multiple myeloma, but the treatment associated morbidity and 
mortality is high (about 20%, due to complications of prolonged 
granulocytopenia) [ 1,2]. Transplantations with stem cells 
Correspondence toC.A. Uyl-de Groot. 
C.A. Uyl-de Groot, A.A.P.M. van Riet and F.F.H. Rutten are at the 
Institute for Medical Technology AssessmentiDepartment of Health 
Care Policy and Management, Erasmus University Rotterdam, P.O. 
Box 1738, 3000 DR Rotterdam; and G.J. Ossenkoppele is at the 
Department of Haematology, Free University Hospital, De Boelelaan 
1117, 1081 HV Amsterdam, The Netherlands. 
Revised 22 Nov. 1993; accepted 21 Jan. 1994. 
derived either from bone marrow or from peripheral blood, and 
or the administration of colony-stimulating factors are perfor- 
med to hasten granulocyte recovery [3,4]. Peripheral blood 
progenitor cell (PBPC) transplantation is increasingly used in 
the treatment of malignancies to alleviate bone marrow toxicity 
resulting from high dose chemotherapy. It is introduced as an 
alternative to autologous bone marrow transplantation (ABMT) 
and has several advantages over ABMT, such as avoiding 
anaesthesia. It seems that infusion of PBPC after high dose 
chemotherapy is associated with markedly accelerated platelets 
and neutrophil recovery as compared to ABMT [4-6]. 
This study focuses on the costs associated with the treatment 
of multiple myeloma patients. The results are based on a 
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retrospective study of detailed records of 26 patients. The 
treatment modalities were high dose melphalan combined with 
or without the granulocyte colony-stimulating factor (G-CSF; 
filgrastim), or G-CSFmobiIised by PBPC transplantation follow- 
ing high dose melphalan. 
PATIENTS AND METHODS 
The study included 26 patients with multiple myeloma. The 
PBPC group consisted of 8 patients. PBPC were mobilised by 
G-CSF subcutaneously, and subsequently 1 1 ofwhole blood was 
collected by phlebotomy, kept unprocessed at room temperature 
and reinfused 24 h after high dose melphalan 171. These patients 
were compared with a group of 18 patients with multiple 
myeloma who met the same criteria and whose pretreatment 
characteristics were equivalent. This group consisted of 11 
patients who received no G-CSF, 4 patients who received G- 
CSF starting at day 28, and 3 patients starting at day 3 after 
chemotherapy. Despite the addition of G-CSF to 7 patients, 
there was no difference with regard to neutrophil and platelet 
recovery, days with fever, number of transfusions or hospital 
stay between these 7 patients and the other 11 patients in the 
control group. 
The costs that were studied concerned days in hospital, 
laboratory services, diagnostics (mainly X-rays), the insertion of 
a subclavian catheter, medication (antibiotics, etc.) and blood 
transfusions. Data on these costs were collected through cost 
registry forms. 
Statistical methods included Wilcoxon tests for comparisons 
of costs and for comparisons of time-to-event outcomes for the 
days in hospital [8]. 
Unit prices 
For each of the activities mentioned above, unit prices were 
determined reflecting the real use of resources. The costs of 
hospital days were divided into direct and indirect costs. The 
direct costs concerned manpower (doctors, nurses, etc.) and 
materials (medical services, supportive patient care, etc.). The 
indirect costs related to overheads. The costs of hospitalisation 
amounted to approximately US$350 per day for normal haema- 
tological care, and US$ 1165 for intensive care. None of the 
patients were treated in a protected environment. 
The output of laboratories in the Netherlands is measured in 
terms of a point system, and by each point (unit of output) a cost 
per unit or price may be associated, which differs across types 
of laboratories. The prices per point varied from US$ 0.62 
(biochemistry and haematology laboratories) to US$ 2.81 
(virology tests), the price of a routine test, (including haemo- 
globin, haematocrit, leucocyte and thrombocyte levels) 
amounted to 5.75 points and cost US$ 3.58. 
For all other diagnostics, the Dutch tariff system has been used 
as an approximation of unit costs (a chest X-ray approximately 
US$31.00 and an electrocardiogram US$22.00). The costs of 
the insertion ofa subclavian catheter were US$ 504.00 (including 
the costs of a catheter). The drug prices used were wholesale 
prices. The costs of 300 mg melphalan (intravenous) amounted 
to US$289.00 and the costs of a 300 trg vial of G-CSF 
(intravenous) to US$ 138.00. (See Appendix for a list of unit 
prices used in this study.) 
Clinical results 
RESULTS 
For the 8 patients treated with high dose melphalan and 
reinfusion of PBPC, the median time to recovery of granulocytes 
Table 1. Clinical results 
Clinical data 
PBPC group Control group 
Melphalan + Melphalan + 
G-CSF + PBPC G-CSF 
Days granulocytes >0.5 x 1OV 12.5 (10-35)’ 38.0 (24-65) 
Days granulocytes >l.Ox IO911 14 (12-55)’ 42 (2672) 
Days platelets >2Ox 1OV 23.5 (M-115)+ 36.0 (25-172) 
Hospital stay in days 19 (N-39)* 43 (33-71) 
Days of antibiotic use 8 (O-37)$ 21 (o-48) 
Number of platelet ransfusions 21 (12-102)* 54 (3&228) 
Number of red cell transfusions 6 Q-21)+ 12 (3-w 
Values are expressed as median (range). *P value < 0.01. +P value 
< 0.05. 
to 0.5 x lo9 was 12.5 days, for recovery of granulocytes to 1.0 
x 109/1 was 14 days, and for platelet recovery to 20 X 109/1 was 
23.5 days (Table 1). In comparison with the control group, 
the pancytopenic period and period to platelet recovery were 
significantly shortened. There was 1 patient whose results 
differed from the control group. This patient had received half 
body irradiation as second line therapy. G-CSF was well tolerated 
and no adverse ffects were observed. Only 1 patient developed 
fever after reinfusion. 
The patients in the PBPC group had a median hospital stay of 
19 days as compared with 43 days in the control group 
(P<O.OOOl) (Figurel). Only 1 patient was treated in the inten- 
sive care department. This patient belonged to the control group 
and stayed there for 6 days. 
The number of days of antibiotic use decreased from 21 to 8 
days. Furthermore, the number of platelet transfusions was 
reduced significantly from 54 to 21 transfusions. The number of 
red cell transfusions also decreased, but the reduction was not 
significant. 
Cost analysis 
Table 2 presents the average treatment costs per category of 
costs. The costs of hospitalisation decreased by more than 
50%, from US$ 16747 to US$ 7335 (P<O.OOS). The costs of 
laboratory services, antibiotics and other medication, nutrition 
and transfusions were also significantly lower in the PBPC 
group. 
The costs of G-CSF were relatively low in the control group, 
because not all patients received G-CSF. The costs of antibiotics 
and other medications reduced markedly, from US$ 6476 to 
1.0 r I - PBPC group 
Days in hospital 
Figure 1. Days in hospital. 
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Table 2. The average treatment costs of multiple myeloma patients 
(U.S$) ( 1 dollar = 1.8 Dutch guilders) 
PBPC group Control group 
Melphalan + Melphalan + 
G-CSF + PBPC G-CSF 
Hospitalisation (hotel) 7335* 16 747 
Laboratory services 767* 1776 
Diagnostics 765* 921 
G-CSF (filgrastim) 5293* 1393* 
Antibiotics and other medication 2454* 6476 
Nutrition 229” 2148 
Transfusions 1065+ 2762 
Total treatment costs 17908* 32 223 
*P value < 0.01. + P value < 0.05. 
US$2454 (IVO.01). When the costs of G-CSF were combined 
with all other medications, the costs in the study group were 
somewhat lower (US$7747 versus US$7869), but this differ- 
ence was not significant. Only 3 patients in the PBPC group 
received total parenteral nutrition, while in the control group all 
patients received parenteral nutrition. The costs of nutrition 
decreased from US$ 2148 to US$229 (P<O.OOl). The costs of 
blood transfusions were reduced by more than 60%, from 
US$ 2762 to US$ 1065 (P<O.OS). The total treatment costs 
decreased by 44% (P<O.OOS). The hospitalisation costs in the 
PBPC group were responsible for 41% of the total costs, and for 
almost 52% in the control group. 
DISCUSSION 
The clinical results of PBPC reinfusion mobilised by G-CSF 
collected by simple phlebotomy without further processing 
showed a remarkable shortening of the haematopoietic recovery 
period in patients with multiple myeloma treated with high dose 
melphalan. The neutropenic recovery was shortened with a 
median of 25.5 days, and the platelet recovery was also acceler- 
ated. This resulted in a remarkable decrease in hospital days and 
reduced use of antibiotics, platelet and red cell transfusions. 
One may argue that the addition of G-CSF to all patients in the 
control group would result in a cost reduction. However, the 
addition of G-CSF did not result in a reduction in the number of 
transfusions or in the length of hospital stay in the patient group 
studied. Therefore, we do not expect a decrease in the total costs 
in the control group when G-CSF is provided to ail patients. 
In general, when new treatment modalities become available, 
the additional financial burden that these treatments place on 
the health care system raises concern. However, in this study, 
PBPC reinfusion mobilised by G-CSF accounted for a remark- 
able reduction in costs. The reduction was observed regarding 
all activities in the treatment process. An improvement in 
the quality of life during the remission period has not been 
documented, but may also be expected. 
PBPC reinfusion appears to be a promising approach with a 
favourable cost-effectiveness profile, but further research is 
needed to show the real benefits from the patient perspective. 
1. Lokhorst HM, Meuwissen OJATh, Verdonck LF, Dekker AW. 
High-risk multiple myeloma treated with high-dose melphalan. J 
Clin Oncol, 1992,10,47-51. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
Selby PJ, McElwain TJ, Nandi AC, et al. Multiple myeloma treated 
with high dose intravenous melphalan. Br ‘j Haemutol 1987, 66. 
55-62. 
Barlogie B, Jagannath S, Dixon D, et al. High dose melphalan 
and granulocy~macrophage colony-stimulating factor for refractory 
multiple myeloma. Blood 1990,76,677-680. 
Kessinger A, Armitage JO, Smith DM, Landmark JD, Bierman PJ, 
Weisenburger DD. High-dose therapy and autologous peripheral 
blood stem cell transplantation for patients with lymphoma. Blood 
1989,74,1260-1265. 
Advani R, Chao NJ, Horning SJ, et al. Granulocyte macrophage 
colony-stimulating factor (GM-CSF) as an adjunct to autologous 
hemopoietic stem cell transplantation for lymphoma. Ann Inrem Med 
1992,116,183-189. 
Siena S, Bregni M, Brando B, Ravagnani F, Bonadonna G, Gianni 
AM. Circulation of CD34’ hematopoietic stem cells in the peripheral 
blood of high-dose cyclophosphamide-treated patients: enhancement 
by intravenous recombinant human granulocyte-macrophage col- 
ony-stimulating factor. Blood 1989,74,1905-1914. 
Ossenkoppele GJ, Jonkhoff AR, Huijgens PC, et al. Peripheral 
blood progenitors mobilised by G-CSF (filgrastim) and reinfused as 
unprocessed autologous whole blood shorten the pancytopenic period 
following high dose melphalan in multiple myeloma. Bme Marrow 
Transplantation 1994,13,37*1. 
Glantz SA. Primer of Btbstatistics. Singapore, McGraw-Hill Book 
Inc., 1989,287-330. 
Acknowledgement-Amgen and Roche are gratefully acknowledged for 
their support during this study. 
APPENDIX 
Items Unit prices 
Hospital stay 
Normal haematological care 
Intensive care 
Laboratories 
Haematology (Hb, Hr, leucocytes, 
thromobocytes) 
Biochemistry (Na, K, creatinine, glucose) 
Urine 1 (pH, glucose, albumin, urobilin. 
bilirubin, sediment) 
Urine 2 (creatinine, Na, albumin, total protein) 
Cultures (blood, urine, sputum) 
Virology tests 
Cytology (bone marrow, bronchus) 
Diagnostics 
X-ray chest 
X-ray sinus 
Electrocardiogram (ECG) 
Bronchoscopy 
Computed tomography scan 
Echo 
Insertion subclavian catheter 
Total parenteral nutrition 
Platelet ransfusions 
Red cell transfusions 
Drugs 
Melphalan (300 mg iv) 
G-CSF (Neupogen) (300 kg iv) 
Antibiotics and other medication: 
e.g. Ciprofloxacin loo0 mg iv 
Fluconazole 50 mg oral 
Tienam 500 mg iv 
Vancomycin 1000 mg iv 
Zovirax 250 mg iv 
Zofran 8 mg iv 
350.00 
1165.00 
3.58 
10.58 
12.47 
8.71 
20.50 
72.94 
42.59 
30.94 
36.92 
22.00 
430.33 
219.44 
74.78 
504.00 
83.33 
74.44 
98.89 
289.00 
138.00 
193.08 
5.18 
23.61 
66.14 
24.98 
34.95 
Hb, haemaglobin; Ht, baematocrit; iv, intravenous. 
